June 30 (Reuters) - Kazia Therapeutics Ltd (KZA) :
- KAZIA THERAPEUTICS LTD - PROVIDES PROGRESS UPDATE ON PAXALISIB AND EVT801 CLINICAL PROGRAMS
- KAZIA THERAPEUTICS LTD - GBM AGILE PIVOTAL STUDY OF PAXALISIB IS RECRUITING AHEAD OF EXPECTATIONS, WITH ALMOST 25 SITES NOW OPEN TO PAXALISIB ARM
- KAZIA THERAPEUTICS LTD - EVT801 PHASE I STUDY PROTOCOL HAS BEEN SUBMITTED TO FRENCH REGULATORY AGENCY FOR REVIEW.
News: KZA Kazia Therapeutics Provides Progress Update On Paxalisib And Evt801 Clinical Programs
Add to My Watchlist
What is My Watchlist?